The brain implant startup, Neuralink, led by billionaire Elon Musk, is currently recruiting individuals with quadriplegia and amyotrophic lateral sclerosis (ALS) to participate in the company's first human clinical trial. The trial aims to evaluate the safety and functionality of the brain-computer interface implantation tools, with the ultimate goal of enabling paralyzed individuals to control external devices through thought. This marks a crucial step forward for Neuralink in advancing the clinical application of brain-computer interfaces following animal trials. The industry anticipates that it may take 2-4 years for Neuralink to receive approval for human implantation, but Musk is more optimistic, believing that if the trial goes smoothly, approval could be obtained as soon as six months. A successful human trial would provide Neuralink with valuable data to support the formal application for approval.